1.1.1
Assess the presence and extent of visceral metastases using a combination of plain radiography, ultrasound, computed tomography (CT) scans and magnetic resonance imaging (MRI). [2009]
Guidance
Recommendations
Recommendations
People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
1.1 Diagnosis and assessment
Imaging assessment
1.1.2
Assess the presence and extent of metastases in the bones of the axial skeleton using bone windows on a CT scan or MRI or bone scintigraphy. [2009]
1.1.3
Assess proximal limb bones for the risk of pathological fracture in patients with evidence of bone metastases elsewhere, using bone scintigraphy and/or plain radiography. [2009]
1.1.4
Use MRI to assess bony metastases if other imaging is equivocal for metastatic disease or if more information is needed (for example, if there are lytic metastases encroaching on the spinal canal). [2009]
1.1.5
Positron emission tomography fused with computed tomography (PET-CT) should only be used to make a new diagnosis of metastases for patients with breast cancer whose imaging is suspicious but not diagnostic of metastatic disease. [2009]
Pathological assessment
1.1.6
On recurrence, consider reassessing oestrogen receptor (ER) and human epidermal growth factor 2 receptor (HER2) status if a change in receptor status will lead to a change in management. [2017]
Monitoring disease status
1.1.7
Do not use bone scintigraphy to monitor the response of bone metastases to treatment. [2009]
1.1.8
Do not use PET-CT to monitor advanced breast cancer. [2009]
1.2 Providing information and support for decision making
1.2.1
Assess the patient's individual preference for the level and type of information. Reassess this as circumstances change. [2009]
1.2.2
On the basis of this assessment, offer patients consistent, relevant information and clear explanations, and provide opportunities for patients to discuss issues and ask questions. [2009]
1.2.3
Assess the patient's individual preference for how much they wish to be involved in decision making. Reassess this as circumstances change. [2009]
1.2.4
Be aware of the value of decision aids and the range available. Make the most appropriate decision aid available to the patient. [2009]
1.3 Systemic disease-modifying therapy
1.3.1
Offer endocrine therapy as first-line treatment for the majority of patients with ER-positive advanced breast cancer. [2009]
1.3.2
Offer chemotherapy as first-line treatment for patients with ER positive advanced breast cancer whose disease is imminently life-threatening or requires early relief of symptoms because of significant visceral organ involvement, providing they understand and are prepared to accept the toxicity. [2009]
1.3.3
For patients with ER-positive advanced breast cancer who have been treated with chemotherapy as their first-line treatment, offer endocrine therapy following the completion of chemotherapy. [2009]
Endocrine therapy
1.3.4
Offer an aromatase inhibitor (either non-steroidal or steroidal) to:
-
postmenopausal women with ER-positive breast cancer and no prior history of endocrine therapy
-
postmenopausal women with ER-positive breast cancer previously treated with tamoxifen. [2009]
1.3.5
Offer tamoxifen and ovarian suppression as first-line treatment to premenopausal and perimenopausal women with ER-positive advanced breast cancer not previously treated with tamoxifen. [2009]
1.3.6
Offer ovarian suppression to premenopausal and perimenopausal women who have previously been treated with tamoxifen and then experience disease progression. [2009]
1.3.7
Offer tamoxifen as first-line treatment to men with ER-positive advanced breast cancer. [2009]
Chemotherapy
1.3.8
On disease progression, offer systemic sequential therapy to the majority of patients with advanced breast cancer who have decided to be treated with chemotherapy. [2009]
1.3.9
Consider using combination chemotherapy to treat patients with advanced breast cancer for whom a greater probability of response is important and who understand and are likely to tolerate the additional toxicity. [2009]
1.3.10
For patients with advanced breast cancer who are not suitable for anthracyclines (because they are contraindicated or because of prior anthracycline treatment either in the adjuvant or metastatic setting), systemic chemotherapy should be offered in the following sequence:
-
first line: single-agent docetaxel
-
second line: single-agent vinorelbine or capecitabine
-
third line: single-agent capecitabine or vinorelbine (whichever was not used as second-line treatment). [2009]
1.3.11
Gemcitabine in combination with paclitaxel, within its licensed indication, is recommended as an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate. (This recommendation is from NICE's technology appraisal guidance on gemcitabine for the treatment of metastatic breast cancer.) [2009]
Biological therapy
1.3.12
For patients who are receiving treatment with trastuzumab for advanced breast cancer, discontinue treatment with trastuzumab at the time of disease progression outside the central nervous system. Do not discontinue trastuzumab if disease progression is within the central nervous system alone. (Recommendations on the use of trastuzumab are covered by NICE's technology appraisal guidance on the use of trastuzumab for the treatment of advanced breast cancer). [2009]
For all technology appraisal guidance relevant to this section, including genomic biomarker‑based therapy, see the NICE topic page on breast cancer. The point at which to use genomic biomarker-based therapy in solid tumour treatment pathways is uncertain. See the NICE topic page on genomic biomarker-based therapy.
1.4 Supportive care
1.4.1
Healthcare professionals involved in the care of patients with advanced breast cancer should ensure that the organisation and provision of supportive care services comply with the recommendations made in NICE's cancer service guidance on improving outcomes in breast cancer and improving supportive and palliative care for adults with cancer, in particular the following two recommendations:
-
'Assessment and discussion of patients' needs for physical, psychological, social, spiritual and financial support should be undertaken at key points (such as diagnosis; at commencement, during, and at the end of treatment; at relapse; and when death is approaching).'
-
'Mechanisms should be developed to promote continuity of care, which might include the nomination of a person to take on the role of "key worker" for individual patients.' [2009]
1.5 Managing complications
Lymphoedema
1.5.1
Discuss with people who have or who are at risk of breast cancer-related lymphoedema that there is no indication that exercise prevents, causes or worsens lymphoedema. [2014]
1.5.2
Discuss with people who have or who are at risk of breast cancer-related lymphoedema that exercise may improve their quality of life. [2014]
1.5.3
Assess patients with lymphoedema for treatable underlying factors before starting any lymphoedema management programme. [2009]
1.5.4
Offer all patients with lymphoedema complex decongestive therapy (CDT) as the first stage of lymphoedema management. [2009]
1.5.5
Consider using multilayer lymphoedema bandaging (MLLB) for volume reduction as a first treatment option before compression hosiery. [2009]
1.5.6
Provide patients with lymphoedema with at least two suitable compression garments. These should be of the appropriate class and size, and a choice of fabrics and colours should be available. [2009]
1.5.7
Provide patients with lymphoedema with clear, written information and the contact details of local and national lymphoedema support groups. [2009]
Uncontrolled local disease
1.5.11
A breast cancer multidisciplinary team should assess all patients presenting with uncontrolled local disease and discuss the therapeutic options for controlling the disease and relieving symptoms. [2009]
1.5.12
A wound care team should see all patients with fungating tumours to plan a dressing regimen and supervise management with the breast care team. [2009]
1.5.13
A palliative care team should assess all patients with uncontrolled local disease in order to plan a symptom management strategy and provide psychological support. [2009]
Bone metastases
1.5.14
Consider offering bisphosphonates to patients newly diagnosed with bone metastases to prevent skeletal-related events and reduce pain. [2009]
1.5.15
The choice of bisphosphonate for patients with bone metastases should be a local decision, taking into account patient preference and limited to preparations licensed for this indication. [2009]
1.5.16
Use external beam radiotherapy in a single fraction of 8Â Gy to treat patients with bone metastases and pain. [2009]
1.5.17
An orthopaedic surgeon should assess all patients at risk of a long bone fracture, to consider prophylactic surgery. [2009]
Brain metastases
1.5.18
Offer surgery followed by whole brain radiotherapy to patients who have a single or small number of potentially resectable brain metastases, a good performance status and who have no or well controlled other metastatic disease. [2009]
1.5.19
Offer whole brain radiotherapy to patients for whom surgery is not appropriate, unless they have a very poor prognosis. [2009]
1.5.20
Offer active rehabilitation to patients who have surgery and/or whole brain radiotherapy. [2009]
1.5.21
Offer referral to specialist palliative care to patients for whom active treatment for brain metastases would be inappropriate. [2009]